Concepedia

Author

Olga Sergeyeva

Renal Research Institute

Also Known As

O P Sergeyeva, O Sergeyeva, O. Sergeyeva, Olga Sergeyeva, Sergeyeva, O.

32

Publications

992

Citations

13

H-Index

13

Concepts

All Affiliations

Renal Research InstituteOtsuka (United States)Pharmaceutical Product Development (United States)University of ChicagoTufts Medical Center
OS

About

Olga Sergeyeva is an author at Renal Research Institute specializing in hemodialysis, chronic kidney disease, and biophysics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

37

2

Medical Laboratory Science

1

1

37

3

Nephrology

1

1

37

4

Biophysics

1

1

37

5

Clinical Chemistry

1

1

37

Olga Sergeyeva

×

12

Publications

943

Citations

12

H-Index

YearCitations

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst,

New England Journal of Medicine

2017

578

A Kinetic Model of Inorganic Phosphorus Mass Balance in Hemodialysis Therapy

Frank A. Gotch, Froilan Panlilio, Olga Sergeyeva,

Blood Purification

2003

73

Effects of Citrate Acid Concentrate (Citrasate®) on Heparin N Requirements and Hemodialysis Adequacy: A Multicenter, Prospective Noninferiority Trial

Jeffrey J. Sands, Peter Kotanko, Jonathan H. Segal,

Blood Purification

2012

64

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst,

Clinical Journal of the American Society of Nephrology

2020

40

RENAL RESEARCH INSTITUTE SYMPOSIUM: Effective Diffusion Volume Flow Rates (<i>Q</i><sub>e</sub>) for Urea, Creatinine, and Inorganic Phosphorous (<i>Q</i><sub>eu</sub>, <i>Q</i><sub>ecr</sub>, <i>Q</i><sub>eiP</sub>) During Hemodialysis

Frank A. Gotch, Froilan Panlilio, Olga Sergeyeva,

Seminars in Dialysis

2003

37

Challenges to enrollment and randomization of the frequent hemodialysis network (FHN) daily trial

Olga Sergeyeva, I. V. Gorodetskaya, Rosio Ramos,

Journal of Nephrology

2012

29

Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.

Yu. P. Istomin, Edvard Zhavrid, E. N. Alexandrova,

PubMed

2008

28

Noninvasive Measurement of Cardiac Output in Hemodialysis Patients by Task Force Monitor: A Comparison with the Transonic System

Thomas M. Kitzler, Olga Sergeyeva, Alice T. Morris,

ASAIO Journal

2007

25

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

Vicente E. Torres, Olivier Devuyst, Arlene B. Chapman,

American Journal of Nephrology

2017

23

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

Ronald D. Perrone, Arlene B. Chapman, Dorothee Oberdhan,

Kidney International Reports

2020

19

Page 1